MSB.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 geg. 2024 @ 03:36):

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland...

Stats
Dzisiejszy wolumen	982 428
Średni wolumen	12.46M
Kapitalizacja rynkowa	1.24B
EPS	$0 ( 2024-02-28 )
Następna data zysków	( $-0.230 ) 2024-07-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.75
ATR14	$0.00500 (0.46%)

Wolumen Korelacja

Długi: 0.18 (neutral)

Krótki: -0.19 (neutral)

Signal:(44.99) Neutral

Mesoblast Ltd Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Mesoblast Ltd Korelacja - Waluta/Towar

0.72
( moderate )

0.54
( weak )

0.00
( neutral )

-0.65
( weak negative )

Mesoblast Ltd Finanse

Annual	2023
Przychody:	$7.50M
Zysk brutto:	$-47.42M (-632.20 %)
EPS:	$-0.110

FY	2023
Przychody:	$7.50M
Zysk brutto:	$-47.42M (-632.20 %)
EPS:	$-0.110

FY	2023
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$0

FY	2022
Przychody:	$10.21M
Zysk brutto:	$-53.36M (-522.58 %)
EPS:	$-0.140

Financial Reports:

No articles found.

Mesoblast Ltd Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Mesoblast Ltd

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.